Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 3/20 | 0.40 |
| ▸ | GABRD | O14764 | 3/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.40 |
| ▸ | GABRE | P78334 | 3/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30284875 | 0.78 | MAOA (0.67) | KDM4ESMN1; SMN2MAOAPIM1GABRP | |
| SCHEMBL2592127 | 0.78 | MAOA (0.67) | KDM4ESMN1; SMN2MAOAPIM1GABRP | |
| SCHEMBL2588529 | 0.76 | PIM1 (0.58) | KDM4ESMN1; SMN2LMNAMAOAPIM1 | |
| SCHEMBL29416622 | 0.76 | PIM1 (0.58) | KDM4ESMN1; SMN2LMNAMAOAPIM1 | |
| SCHEMBL10748556 | 0.75 | HSP90AA1 (0.41) | KDM4ESMN1; SMN2LMNAPIM1MAPT | |
| SCHEMBL2370924 | 0.74 | GABRP (0.46) | KDM4ESMN1; SMN2LMNAPIM1GABRP | |
| SCHEMBL67700 | 0.70 | MAPT (0.59) | KDM4ESMN1; SMN2LMNAMAOAPIM1 | |
| SCHEMBL29886872 | 0.70 | MAPT (0.59) | KDM4ESMN1; SMN2LMNAMAOAPIM1 | |
| SCHEMBL635182 | 0.70 | MAPT (0.59) | KDM4ESMN1; SMN2LMNAMAOAPIM1 | |
| SCHEMBL47040 | 0.70 | PIM1 (0.51) | KDM4ESMN1; SMN2LMNAMAOAPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| WO-2012109165-A1 | 5-AMINO-OXAZEPINE AND 5-AMINO-THIAZEPANE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012071279-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 2994/4885SMN1; SMN2 2369/4885LMNA 1131/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 3745/4885SMN1; SMN2 2585/4885LMNA 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.